A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion

Purpose: To compare the efficacy of intravitreal injection of ranibizumab, dexamethasone implant and aflibercept for the management of macular edema (ME) related to branch retinal vein occlusion (BRVO). Methods: This retrospective and comparative study included 62 eyes of 62 patients with BRVO and ME. Patients received one of the following treatments: 0.5 mg ranibizumab (group 1, n = 22), 0.7 mg dexamethasone implant (group 2, n = 20) and 2 mg aflibercept (group 3, n = 20). The 6-month treatment protocol in groups 1 and 3 consisted of 3-dose loading treatment for the first 3 months and followed by repeat injections based on clinical necessity. Group 2 received only single dose of 0.7 mg dexamethasone implant for 6 months. Visual acuity (VA), central macular thickness (CMT), serous retinal detachment (SRD) height and intraocular pressure (IOP) measurements were done at baseline and first 6 months of follow-up. Results: At baseline, the groups did not differ in age, gender, duration of ME, VA, CMT, IOP and SRD height (p > 0.05). Mean number of injections per eye within six months were 3.64 ± 0.49 (range 3–4) in group 1, only 1 in group 2 and 3.35 ± 0.49 (range 3–4) in group 3.VA was significantly better in group 2 in first 3 months but it became the worst among three groups in sixth month. CMT did not differ between groups in first 3 months, but it was significantly higher in group 2 at sixth month. SRD height was significantly lower in group 2 in first 3 months, but there was no difference between the groups at the end of the sixth month. IOP was significantly higher in group 2 in third and sixth months. Conclusion: In the treatment of ME associated with BRVO, dexamethasone implant appears to be more advantageous in terms of VA and SRD height for the first 3 months. However, at the end of the sixth month of treatment, anti-VEGF drugs were more efficient in maintaining the increased visual acuity and reduced CMT. A dexamethasone implant may be the first treatment option in BRVO cases with high SRD. © 2017, Springer Science+Business Media B.V.

Dergi Adı International Ophthalmology
Dergi Cilt Bilgisi 38
Dergi Sayısı 4
Sayfalar 1549 - 1558
Yayın Yılı 2018
Eser Adı
[dc.title]
A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion
Yazar
[dc.contributor.author]
Kaldırım H.E.
Yazar
[dc.contributor.author]
Yazgan S.
Yayın Yılı
[dc.date.issued]
2018
Yayıncı
[dc.publisher]
Springer Netherlands
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Purpose: To compare the efficacy of intravitreal injection of ranibizumab, dexamethasone implant and aflibercept for the management of macular edema (ME) related to branch retinal vein occlusion (BRVO). Methods: This retrospective and comparative study included 62 eyes of 62 patients with BRVO and ME. Patients received one of the following treatments: 0.5 mg ranibizumab (group 1, n = 22), 0.7 mg dexamethasone implant (group 2, n = 20) and 2 mg aflibercept (group 3, n = 20). The 6-month treatment protocol in groups 1 and 3 consisted of 3-dose loading treatment for the first 3 months and followed by repeat injections based on clinical necessity. Group 2 received only single dose of 0.7 mg dexamethasone implant for 6 months. Visual acuity (VA), central macular thickness (CMT), serous retinal detachment (SRD) height and intraocular pressure (IOP) measurements were done at baseline and first 6 months of follow-up. Results: At baseline, the groups did not differ in age, gender, duration of ME, VA, CMT, IOP and SRD height (p > 0.05). Mean number of injections per eye within six months were 3.64 ± 0.49 (range 3–4) in group 1, only 1 in group 2 and 3.35 ± 0.49 (range 3–4) in group 3.VA was significantly better in group 2 in first 3 months but it became the worst among three groups in sixth month. CMT did not differ between groups in first 3 months, but it was significantly higher in group 2 at sixth month. SRD height was significantly lower in group 2 in first 3 months, but there was no difference between the groups at the end of the sixth month. IOP was significantly higher in group 2 in third and sixth months. Conclusion: In the treatment of ME associated with BRVO, dexamethasone implant appears to be more advantageous in terms of VA and SRD height for the first 3 months. However, at the end of the sixth month of treatment, anti-VEGF drugs were more efficient in maintaining the increased visual acuity and reduced CMT. A dexamethasone implant may be the first treatment option in BRVO cases with high SRD. © 2017, Springer Science+Business Media B.V.
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Konu Başlıkları
[dc.subject]
Aflibercept
Konu Başlıkları
[dc.subject]
Branch retinal vein occlusion
Konu Başlıkları
[dc.subject]
Dexamethasone implant
Konu Başlıkları
[dc.subject]
Ranibizumab
Konu Başlıkları
[dc.subject]
Serous retinal detachment
Haklar
[dc.rights]
info:eu-repo/semantics/closedAccess
ISSN
[dc.identifier.issn]
0165-5701
İlk Sayfa Sayısı
[dc.identifier.startpage]
1549
Son Sayfa Sayısı
[dc.identifier.endpage]
1558
Dergi Adı
[dc.relation.journal]
International Ophthalmology
Dergi Sayısı
[dc.identifier.issue]
4
Dergi Cilt Bilgisi
[dc.identifier.volume]
38
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.1007/s10792-017-0618-z
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/3910
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
33
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
25 Şubat 2024 01:21
Google Kontrol
Tıklayınız
groups 3 months implant dexamethasone treatment significantly height (group 3–4) n = 20) acuity 6 months higher between injections baseline ranibizumab aflibercept differ macular retinal received (range months number better 64 ± 0 35 ± 0 (p > 0 within Purpose became visual reduced option
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms